Parker Hannifin will use CPHI Milan in October to present sterile-filtration, single-use, sensing, and process-control systems aimed at pharmaceutical manufacturers dealing with contamination control, filter-integrity testing, and increasingly complex validated production routes.
The company will exhibit from 6 to 8 October at Fiera Milano, where it is listed on stand 12M45 within the exhibition’s bioprocess technology and biomanufacturing categories. Equipment highlighted for the event includes PureTain single-use assemblies, SciLog NFF+ systems, SciLog pumps and sensors, and PROPOR sterilising-grade filters.
The announcement is an exhibition preview rather than a new factory investment or major product launch, but the engineering package centres on a practical regulatory issue: how pharmaceutical manufacturers incorporate pre-use post-sterilisation integrity testing into sterile-filtration processes without adding unnecessary interventions to an already controlled fluid path.
PUPSIT is used to establish that a sterilising-grade filter remains integral after sterilisation and before product filtration. In an aseptic manufacturing environment, carrying out that test requires control of air and fluid pathways so that verifying the filter does not itself introduce contamination downstream.
Parker’s SciLog NFF+ range combines normal-flow filtration with single-use sensing and automated or semi-automated control. Its PUPSIT configurations can sequence valve positions and process steps, monitor pressure, and work with an integrity tester to carry out pre-use and post-use checks within a defined flow path.
Jean-Philippe Minne, platform sales leader Biopharma at Parker Hannifin, said: “Pharmaceutical manufacturers are under increasing pressure to strengthen process reliability, reduce contamination risk, and maintain compliance while keeping operations efficient.”
That balance is difficult because additional controls can themselves increase process complexity. Every temporary hose, valve movement, connector, sampling point, and operator intervention creates another condition that has to be understood and controlled, particularly after the downstream side of a sterile filter has been established as clean.
Automation can reduce some of that dependence on manual sequencing. Parker’s SciLog NFF+ documentation describes predefined valve-control steps, alarms and interlocks, pressure monitoring, and touchscreen control, allowing operators to execute PUPSIT as part of the process sequence before moving into product filtration.
The system still depends on a correctly designed process. Automated valves cannot compensate for an unsuitable filter, poorly arranged fluid path, incorrect integrity-test parameters, or contamination introduced elsewhere, but they can make repeatable execution easier and generate clearer evidence of how the filtration stage was operated.
Parker’s PureTain assemblies address the same problem from the disposable-fluid-path side. Tubing, containers, connectors, sampling points, sensors, and filters can be supplied as preconfigured single-use assemblies rather than being assembled from individual components immediately before a batch.
The company offers PUPSIT-specific PureTain assemblies with enclosed fluid paths and configurable tubing, filtration, sampling, and connection options. They can be supplied pre-sterilised or in forms ready for sterilisation and can operate as standalone assemblies or as part of an automated system.
Single-use technology has become established in biopharmaceutical production because it can reduce cleaning requirements and shorten changeovers between products. It also transfers some responsibility from the manufacturing site to the component supplier, which must maintain material consistency, sterilisation control, component traceability, and dependable supply of assemblies that may form part of a validated process.
That dependency explains why Parker is also discussing dual sourcing and supply-chain uncertainty at CPHI. A manufacturer cannot always substitute a different hose, bag, connector, membrane, or sensor immediately when supply is interrupted, because changing a product-contact component can trigger technical assessment, validation work, and regulatory documentation.
Standardisation can reduce the number of unique components that need to be qualified and stocked, although pharmaceutical processes remain highly application-specific. Flow rate, tubing diameter, hold-up volume, sterilisation method, connector type, filter area, pressure limit, sensing requirements, and material compatibility all influence the final assembly design.
Sterilising-grade filters form another part of Parker’s exhibit. Its PROPOR SG range uses polyethersulphone membranes for pharmaceutical liquids, with the company offering integrity-testable configurations and PFAS-free constructions. Higher-capacity members of the wider PROPOR family are intended to increase throughput where process fluids would otherwise cause premature blockage.
Filter area cannot be treated as a universal productivity figure. Actual throughput depends on the fluid, particulate and biological load, viscosity, pressure, membrane selection, and required batch time, making sizing studies and validation necessary before changing a filtration system simply because a newer element has a larger nominal surface area.
PFAS-free options create a similar engineering trade-off. Pressure to reduce fluorinated materials is increasing, but changing a material in a pharmaceutical flow path requires evidence that the replacement provides suitable chemical compatibility, extractables performance, sterilisation resistance, and mechanical reliability.
Parker will therefore be discussing several subjects that converge at the same manufacturing interface: Annex 1 expectations, PUPSIT, closed processing, component sourcing, single-use technology, automation, sensing, filter performance, and material selection.
CPHI itself remains the venue rather than the news. Parker has not attached a major capital project or single breakthrough launch to its Milan appearance, so the useful industrial angle lies in how these systems address validated sterile manufacturing rather than in the stand number or exhibition invitation.
That is also why contamination-control engineering tends to attract less attention than more visible pharmaceutical technologies. A filter, valve sequence, disposable manifold, or pressure sensor rarely changes the therapeutic value of a medicine, but failure at that point can stop a batch reaching patients at all.
Parker’s CPHI package is ultimately about making those routine steps more controlled and repeatable. The test of the equipment will not be how convincingly it operates on an exhibition stand, but whether manufacturers can use it to reduce interventions and process complexity without introducing another set of components that are difficult to validate, source, and maintain.
